Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial

Hoda Taheri,Mojtaba Malek,Faramarz Ismail-Beigi,Farhad Zamani,Masoudreza Sohrabi,Mohammad Reza babaei,Mohammad E. Khamseh
DOI: https://doi.org/10.1007/s12325-020-01498-5
2020-09-25
Advances in Therapy
Abstract:Despite the high prevalence of non-alcoholic fatty liver disease (NAFLD) and its associated co-morbidities, no efficient treatment in a high percentage of individuals is available. Beneficial effects of sodium–glucose co-transporter 2 inhibitors on fatty liver have been investigated in people with type 2 diabetes (T2DM). The aim of this study was to explore the effect of empagliflozin on liver steatosis and fibrosis in patients with NAFLD without T2DM.
pharmacology & pharmacy,medicine, research & experimental
What problem does this paper attempt to address?